Placeholder

Fatty Liver Disease – Pipeline Insights, 2015

$1250 - $4000

No. of Pages

60

Release Date

31-12-2015

Delivery Format

PDF

Geographical Coverage

Worldwide

Pricing

Enquire for discount Inquiry Before Buying

Summary
DelveInsight’s, Fatty Liver Disease- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Fatty Liver Disease. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Fatty Liver Disease Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, Fatty Liver Disease- Pipeline Insights, 2015 Report covers the Fatty Liver Disease pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Fatty Liver Disease related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Fatty Liver Disease.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– DelveInsight’s report provides a Fatty Liver Disease Landscape across the globe
– The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
– Coverage of the Fatty Liver Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Fatty Liver Disease and also provide company profiling
– Pipeline products coverage based on various stages of development from NDA filings to discovery.
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Fatty Liver Disease
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Track your competitors and develop strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
– Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table of Contents
• Fatty Liver Disease Overview
• Fatty Liver Disease Pipeline Therapeutics
• Fatty Liver Disease Therapeutics under Development by Companies
• Fatty Liver Disease Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Fatty Liver Disease Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Fatty Liver Disease Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Fatty Liver Disease Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Fatty Liver Disease – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Fatty Liver Disease – Discontinued Products
• Fatty Liver Disease – Dormant Products
• Companies Involved in Therapeutics Development for Fatty Liver Disease
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Fatty Liver Disease, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Fatty Liver Disease Assessment by Monotherapy Products
• Fatty Liver Disease Assessment by Combination Products
• Fatty Liver Disease Assessment by Route of Administration
• Fatty Liver Disease Assessment by Stage and Route of Administration
• Fatty Liver Disease Assessment by Molecule Type
• Fatty Liver Disease Assessment by Stage and Molecule Type
• Fatty Liver Disease Therapeutics – Discontinued Products
• Fatty Liver Disease Therapeutics – Dormant Products
• Products under Development by Companies, 2015
List of Figures
• Number of Products under Development for Fatty Liver Disease, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Fatty Liver Disease Assessment by Monotherapy Products
• Fatty Liver Disease Assessment by Combination Products
• Fatty Liver Disease Assessment by Route of Administration
• Fatty Liver Disease Assessment by Stage and Route of Administration
• Fatty Liver Disease Assessment by Molecule Type
• Fatty Liver Disease Assessment by Stage and Molecule Type

This healthcare and pharma insights & market research report requires few ‘real-time updates’, in addition to all readily available information, which may take 48 to 72 hours (excluding weekends and public holidays) of processing and complete report delivery after placing an order.

Category

Publisher

DelveInsight